Alexander L Rakhmilevich
Overview
Explore the profile of Alexander L Rakhmilevich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rakhmilevich A, Tsarovsky N, Felder M, Zaborek J, Moram S, Erbe A, et al.
Front Immunol
. 2024 Jul;
15:1419773.
PMID: 39076988
Background: The majority of experimental approaches for cancer immunotherapy are tested against relatively small tumors in tumor-bearing mice, because in most cases advanced cancers are resistant to the treatments. In...
2.
Zebertavage L, Schopf A, Nielsen M, Matthews J, Erbe A, Aiken T, et al.
J Clin Med
. 2024 May;
13(9).
PMID: 38731089
: Incorporating GD2-targeting monoclonal antibody into post-consolidation maintenance therapy has improved survival for children with high-risk neuroblastoma. However, ~50% of patients do not respond to, or relapse following, initial treatment....
3.
Pieper A, Stowe N, Periyasamy S, Burkel B, Tsarovsky N, Singh A, et al.
J Vasc Interv Radiol
. 2024 Mar;
35(6):900-908.e2.
PMID: 38508448
Purpose: To develop a noninvasive therapeutic approach able to alter the biophysical organization and physiology of the extracellular matrix (ECM) in breast cancer. Materials And Methods: In a 4T1 murine...
4.
Jin W, Jagodinsky J, Vera J, Clark P, Zuleger C, Erbe A, et al.
Cell Rep
. 2023 Dec;
42(12):113556.
PMID: 38096050
We report an in situ vaccination, adaptable to nearly any type of cancer, that combines radiotherapy targeting one tumor and intratumoral injection of this site with tumor-specific antibody and interleukin-2...
5.
Tsarovsky N, Felder M, Heck M, Slowinski J, Rasmussen K, VandenHeuvel S, et al.
Front Oncol
. 2023 Sep;
13:1200436.
PMID: 37746303
Introduction: We have previously shown that an intratumoral (IT) injection of the hu14.18-IL2 immunocytokine (IC), an anti-GD2 antibody linked to interleukin 2, can serve as an vaccine and synergize with...
6.
Pieper A, Spiegelman D, Felder M, Feils A, Tsarovsky N, Zaborek J, et al.
Cancer Immunol Immunother
. 2023 Apr;
72(7):2459-2471.
PMID: 37016127
Background: The in-situ vaccine using CpG oligodeoxynucleotide combined with OX40 agonist antibody (CpG + OX40) has been shown to be an effective therapy activating an anti-tumor T cell response in...
7.
Carlson P, Patel R, Birstler J, Rodriquez M, Sun C, Erbe A, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36639155
Background: The antitumor effects of external beam radiation therapy (EBRT) are mediated, in part, by an immune response. We have reported that a single fraction of 12 Gy EBRT combined...
8.
Kravtsov D, Erbe A, Sondel P, Rakhmilevich A
Front Immunol
. 2022 Sep;
13:972021.
PMID: 36159781
It has been well established that CD8+ T cells serve as effector cells of the adaptive immune response against tumors, whereas CD4+ T cells either help or suppress the generation...
9.
Zhang Y, Sriramaneni R, Clark P, Jagodinsky J, Ye M, Jin W, et al.
Nat Commun
. 2022 Aug;
13(1):4948.
PMID: 35999216
Radiation therapy (RT) activates an in situ vaccine effect when combined with immune checkpoint blockade (ICB), yet this effect may be limited because RT does not fully optimize tumor antigen...
10.
Aiken T, Erbe A, Zebertavage L, Komjathy D, Feils A, Rodriguez M, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35618290
Background: Most pediatric cancers are considered immunologically cold with relatively few responding to immune checkpoint inhibition. We recently described an effective combination radio-immunotherapy treatment regimen ( ombination daptive- nnate immunotherapy...